Single answer
Is Aardvark Therapeutics Inc Common (AARD) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Aardvark Therapeutics Inc Common Stock is $25.67, which is $12.44 (94.03%) above the current price today's price.
Low target: $18.00 | High target: $35.00
Company snapshot
A quick overview of the business and its public profile.
Aardvark Therapeutics Inc a clinicalstage biopharmaceutical company focuses on developing smallmolecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases Its lead product candidate is the ARD101 an oral gutrestricted smallmolecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with PraderWilli Syndrome as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma including surgery or radiation It also developing ARD201 which is in Phase I clinical trial for the treatment of obesity The company was incorporated in 2017 and is based in San Diego California
Website: https://aardvarktherapeutics.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: -82.73. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Aardvark Therapeutics Inc Common is $2.2M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Aardvark Therapeutics Inc Common 10 years ago, but if you had invested on 2025-02-13 when the price was $14.31, you would have made a loss of $1.080 per share or 7.55%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.